Isis Pharmaceuticals Inc., a maker of gene therapy treatments, may seek to expand use of an experimental drug targeting triglycerides to fight heart disease, a move an analyst says could add $2 billion in sales.
Scientists have identified gene mutations that reduce levels of fatty triglycerides in some people and cut their risks for a heart attack, potentially paving the way for new types of drugs.
Indian drugmaker Cipla Ltd. may be the industry’s next target in a record run of takeovers.
Where you live may affect your decisions and your health, say researchers who suggest designing cities to be better for walking could reduce diabetes.
Rejuvenan’s Nazem Says Diet Not Drugs Key to Health (Audio)